Richard Gelber

Professor in the Department of Biostatistics

Biostatistics, Harvard T.H. Chan School of Public Health

Departments

Department of Biostatistics

Other Positions

Professor of Pediatrics (Biostatistics)

Pediatrics-Boston Children's Hospital, Harvard Medical School

Biography

Richard's Catalyst Profile

Publications

Final analysis of the ALTTO trial: adjuvant trastuzumab in sequence or in combination with lapatinib in patients with HER2-positive early breast cancer [BIG 2-06/NCCTG N063D (Alliance)].

de Azambuja E, Piccart-Gebhart M, Fielding S, Townend J, Hillman DW, Colleoni M, Roylance R, Kelly CM, Lombard J, El-Abed S, Choudhury A, Korde L, Vicente M, Chumsri S, Rodeheffer R, Ellard SL, Wolff AC, Holtschmidt J, Lang I, Untch M, Boyle F, Xu B, Werutsky G, Tujakowski J, Huang CS, Baruch NB, Bliss J, Ferro A, Gralow J, Kim SB, Kroep JR, Krop I, Kuemmel S, McConnell R, Moscetti L, Knop AS, van Duijnhoven F, Gomez H, Cameron D, Di Cosimo S, Gelber RD, Moreno-Aspitia A. ESMO Open 2024
Reply to Z Wen et al and S Liu et al.

Azim HA, Niman SM, Partridge AH, Demeestere I, Ruggeri M, Gelber RD, Pagani O, Peccatori FA. J Clin Oncol 2024
Adjuvant Pertuzumab and Trastuzumab in Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the APHINITY Trial: Third Interim Overall Survival Analysis With Efficacy Update.

Loibl S, Jassem J, Sonnenblick A, Parlier D, Winer E, Bergh J, Gelber RD, Restuccia E, Im YH, Huang CS, Dalenc F, Calvo I, Procter M, Caballero C, Clark E, Raimbault A, McConnell R, Monturus E, de Azambuja E, Gomez HL, Bliss J, Viale G, Bines J, Piccart M. J Clin Oncol 2024
Correction: Surgery of the primary tumor in patients with de novo metastatic breast cancer: a nationwide population-based retrospective cohort study in Belgium.

Brandão M, Martins-Branco D, De Angelis C, Vuylsteke P, Gelber RD, Van Damme N, van Walle L, Ferreira AR, Lambertini M, Poggio F, Verhoeven D, Barbeaux A, Duhoux FP, Wildiers H, Caballero C, Awada A, Piccart-Gebhart M, Punie K, de Azambuja E. Breast Cancer Res Treat 2024
Outcomes of patients with advanced solid tumors who discontinued immune-checkpoint inhibitors: a systematic review and meta-analysis.

Pala L, Pagan E, Sala I, Oriecuia C, Oliari M, De Pas T, Specchia C, Cocorocchio E, Zattarin E, Rossi G, Catania C, Ceresoli GL, Laszlo D, Canzian J, Valenzi E, Viale G, Gelber RD, Mantovani A, Bagnardi V, Conforti F. EClinicalMedicine 2024

View more publications

Unleash your potential at Harvard Chan School.

In addition to our degree programs, we offer highly targeted executive and continuing education, directed and taught by Harvard faculty.

Degree Programs

How to Apply

Executive and Continuing Education

Biography

Publications

Final analysis of the ALTTO trial: adjuvant trastuzumab in sequence or in combination with lapatinib in patients with HER2-positive early breast cancer [BIG 2-06/NCCTG N063D (Alliance)].

Reply to Z Wen et al and S Liu et al.

Adjuvant Pertuzumab and Trastuzumab in Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the APHINITY Trial: Third Interim Overall Survival Analysis With Efficacy Update.

Correction: Surgery of the primary tumor in patients with de novo metastatic breast cancer: a nationwide population-based retrospective cohort study in Belgium.

Outcomes of patients with advanced solid tumors who discontinued immune-checkpoint inhibitors: a systematic review and meta-analysis.

Unleash your potential at Harvard Chan School.